-
New UCL staff guidance on supporting working parents and carers
The Cancer Institute / UCL staff guidance on supporting working parents and carers is now available: view UCL web site to download the current policy. .....
-
Tyrosine Kinase BMX Phosphorylates Phosphotyrosine-Primed Motif Mediating the Activation of Multiple Receptor Tyrosine Kinases
. Chen*, X. Jiang*, C. A. Gewinner et al. The Tec family tyrosine kinase BMX (bone marrow tyrosine kinase gene on chromosome X) is broadly expressed and activated downstream of phosphatidylinositol-3 kinase .....
-
Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer (SOC) and a BRCA mutation (BRCAm).
Jonathan Ledermann, MD, UCL Cancer Institute, University College London and lead study investigator, said: "These are encouraging results for patients with ovarian cancer who carry a BRCA mutation.....
-
Cancer Institute Staff races in London Marathon !
11 runners took on the 26.2 miles of the London Marathon on 21st April, the warmest weekend of the year after having trained through some of the coldest spring conditions we have had in 100 years....
-
UCL Cancer Institute-led study defines standard of care for non-Hodgkin lymphoma
from the CR-UK UCL Clinical Trials Centre.
Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensifi cation with 14-day versus 21-day cycles....
-
MSc Cancer, applications are now being accepted for the 2013-2014 academic year.
Please apply early to avoid disappointment. The closing date for applications is 2nd August 2013. There is a maximum of 35 students accepted onto the program per annum. ..
stop
stop
stop
stop
stop
stop